NCT05045872View on ClinicalTrials.gov

Assessment of Renal Vasculature and Function with Ferumoxytol-enhanced Magnetic Resonance Imaging

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 17, 2021

Primary Completion Date

May 25, 2024

Study Completion Date

September 3, 2024

Conditions
Chronic Kidney Diseases
Interventions
DRUG

domestic polysaccharide superparamagnetic iron oxide nanoparticle

Patients will receive contrast-enhanced renal magnetic resonance imaging with polysaccharide superparamagnetic iron oxide nanoparticle before renal angiography. Patients received intravenous polysaccharide superparamagnetic iron oxide nanoparticle before magnetic resonance imaging.

Trial Locations (1)

210029

First Affiliated Hospital of Nanjing Medical University, Nanjing

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER